Clinical Trial Update: Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of Technosphere insulin (inhaled) versus subcutaneous premixed insulin over 52 weeks in adults with type 2 diab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)
• insulin premixed therapy (premixed subcutaneous insulin)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2014-10-16